Key Takeaways Allurion Technologies said it planned to test its gastric balloon with the key ingredient in popular ...

Allurion, while battling declining revenues, is targeting the loss in muscle mass seen in patients on GLP-1RA therapy.

Allurion catapulted Friday after the company said it plans to test its weight-loss technology with an obesity drug.

Allurion Technologies (ALUR) stock climbed 200% despite a ~7.4M stock and warrants offering announced by the company. Read ...

Allurion stock soars on weight-loss therapy update. Stardust Power breaks ground on Oklahoma lithium refinery. OpenAI ...

Shares of Allurion Technologies ( ALUR, Financials) surged 185% to $10.54 in midday trading after the company announced plans ...

Allurion Technologies (NYSE: ALUR) shares are moving higher Friday potentially after after the company announced plans to conduct a clinical study evaluating the combination of its Allurion Program ...

In one research, over four months participants on the Allurion Program showed a 14% drop in overall weight and a 5.6% gain in lean body mass. Another trial revealed a 15.7% weight decrease devoid of ...

This is where Allurion’s unique approach comes into play. Previous studies have demonstrated that patients using the Allurion Gastric Balloon in combination with the Allurion Virtual Care Suite ...

Allurion Technologies (ALUR) announced that it has entered into a definitive securities purchase agreement with certain institutional investors ...

Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered into a definitive securities purchase agreement with ...